Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion

Science Signaling

Volumn 8, Issue 389, 2015, Pages

  Rivadeneira, Dayana B ^a   Caino, M Cecilia ^a   Seo, Jae Ho ^a   Angelin, Alessia ^b   Wallace, Douglas C ^b   Languino, Lucia R ^c   Altieri, Dario C ^a  

^a WISTAR INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SEPANTRONIUM BROMIDE; SUCCINATE DEHYDROGENASE (UBIQUINONE); SURVIVIN; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOENERGY; BREAST ADENOCARCINOMA; CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL RESPIRATION; CONTROLLED STUDY; CYTOSKELETON; ENERGY RESOURCE; FOCAL ADHESION; HUMAN; HUMAN CELL; MALE; MCF 7 CELL LINE; METABOLISM; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; REGULATORY MECHANISM; TUMOR CELL; TUMOR CELL LINE; TURNOVER TIME; CELL MOTION; FEMALE; GENETICS; MCF-7 CELL LINE; NEOPLASM; OXYGEN CONSUMPTION; PATHOLOGY; TUMOR INVASION;

CELL MOVEMENT; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MCF-7 CELLS; MITOCHONDRIA; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION;

EID: 84939142927     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aab1624     Document Type: Article

References (55)

1. D. C. Altieri, Survivin-The inconvenient IAP. Semin. Cell Dev. Biol. 39, 91-96 (2015).
2. S. Fulda, D. Vucic, Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 11, 109-124 (2012).
3. T. Dohi, E. Beltrami, N. R. Wall, J. Plescia, D. C. Altieri, Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J. Clin. Invest. 114, 1117-1127 (2004).
4. T. Dohi, F. Xia, D.C. Altieri, Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol. Cell 27, 17-28 (2007).
5. J. Hagenbuchner, A. V. Kuznetsov, P. Obexer, M. J. Ausserlechner, BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene 32, 4748-4757 (2013).
6. D. C. Wallace, Mitochondria and cancer. Nat. Rev. Cancer 12, 685-698 (2012).
7. N. C. Denko, Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer 8, 705-713 (2008).
8. M. G. Vander Heiden, L. C. Cantley, C. B. Thompson, Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
9. G. Kroemer, J. Pouyssegur, Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 13, 472-482 (2008).
10. S. Turcan, D. Rohle, A. Goenka, L.A. Walsh, F. Fang, E. Yilmaz, C. Campos, A.W. Fabius, C. Lu, P. S.Ward, C. B. Thompson, A. Kaufman, O. Guryanova, R. Levine, A. Heguy, A. Viale, L. G. Morris, J. T. Huse, I. K. Mellinghoff, T. A. Chan, IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479-483 (2012).
11. M. A. Selak, S. M. Armour, E. D.MacKenzie, H. Boulahbel, D. G.Watson, K. D. Mansfield, Y. Pan, M.C. Simon, C. B. Thompson, E. Gottlieb, Succinate linksTCAcycle dysfunction to oncogenesis by inhibiting HIF-a prolyl hydroxylase. Cancer Cell 7, 77-85 (2005).
12. P. S. Ward, C. B. Thompson, Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 21, 297-308 (2012).
13. E. Gottlieb, I. P. Tomlinson, Mitochondrial tumour suppressors: A genetic and biochemical update. Nat. Rev. Cancer 5, 857-866 (2005).
14. C. Jose, N. Bellance, R. Rossignol, Choosing between glycolysis and oxidative phosphorylation: A tumor's dilemma? Biochim. Biophys. Acta 1807, 552-561 (2011).
15. M. Janiszewska, M. L. Suvà, N. Riggi, R. H. Houtkooper, J. Auwerx, V. Clément-Schatlo, I. Radovanovic, E. Rheinbay, P. Provero, I. Stamenkovic, Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 26, 1926-1944 (2012).
16. A. Viale, P. Pettazzoni, C. A. Lyssiotis, H. Ying, N. Sánchez, M. Marchesini, A. Carugo, T. Green, S. Seth, V. Giuliani, M. Kost-Alimova, F. Muller, S. Colla, L. Nezi, G. Genovese, A. K. Deem, A. Kapoor, W. Yao, E. Brunetto, Y. Kang, M. Yuan, J. M. Asara, Y. A. Wang, T. P. Heffernan, A. C. Kimmelman, H. Wang, J. B. Fleming, L. C. Cantley, R. A. DePinho, G. F. Draetta, Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514, 628-632 (2014).
17. A. Roesch, A. Vultur, I. Bogeski, H. Wang, K. M. Zimmermann, D. Speicher, C. Körbel, M. W. Laschke, P. A. Gimotty, S. E. Philipp, E. Krause, S. Pätzold, J. Villanueva, C. Krepler, M. Fukunaga-Kalabis, M. Hoth, B. C. Bastian, T. Vogt, M. Herlyn, Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells. Cancer Cell 23, 811-825 (2013).
18. W. E. Balch, R. I. Morimoto, A. Dillin, J. W. Kelly, Adapting proteostasis for disease intervention. Science 319, 916-919 (2008).
19. C. M. Haynes, D. Ron, The mitochondrial UPR-Protecting organelle protein homeostasis. J. Cell Sci. 123, 3849-3855 (2010).
20. Y. C. Chae, M. C. Caino, S. Lisanti, J. C. Ghosh, T. Dohi, N. N. Danial, J. Villanueva, S. Ferrero, V. Vaira, L. Santambrogio, S. Bosari, L. R. Languino, M. Herlyn, D. C. Altieri, Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Cancer Cell 22, 331-344 (2012).
21. B. H. Kang, J. Plescia, T. Dohi, J. Rosa, S. J. Doxsey, D. C. Altieri, Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 131, 257-270 (2007).
22. Y. C. Chae, A. Angelin, S. Lisanti, A. V. Kossenkov, K. D. Speicher, H.Wang, J. F. Powers, A. S. Tischler, K. Pacak, S. Fliedner, R. D. Michalek, E. D. Karoly, D. C. Wallace, L. R. Languino, D. W. Speicher, D. C. Altieri, Landscape of the mitochondrial Hsp90 metabolome in tumours. Nat. Commun. 4, 2139 (2013).
23. L. A. Lavery, J. R. Partridge, T. A. Ramelot, D. Elnatan, M. A. Kennedy, D. A. Agard, Structural asymmetry in the closed state of mitochondrial Hsp90 (TRAP1) supports a two-step ATP hydrolysis mechanism. Mol. Cell 53, 330-343 (2014).
24. E. Beltrami, J. Plescia, J. C. Wilkinson, C. S. Duckett, D. C. Altieri, Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J. Biol. Chem. 279, 2077-2084 (2004).
25. E. T. Roussos, J. S. Condeelis, A. Patsialou, Chemotaxis in cancer. Nat. Rev. Cancer 11, 573-587 (2011).
26. F. J. Sulzmaier, C. Jean, D. D. Schlaepfer, FAK in cancer: Mechanistic findings and clinical applications. Nat. Rev. Cancer 14, 598-610 (2014).
27. T. Hara, A. Takamura, C. Kishi, S. Iemura, T. Natsume, J. L. Guan, N. Mizushima, FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells. J. Cell Biol. 181, 497-510 (2008).
28. S. Mehrotra, L. R. Languino, C. M. Raskett, A. M. Mercurio, T. Dohi, D. C. Altieri, IAP regulation of metastasis. Cancer Cell 17, 53-64 (2010).
29. S. Fulda, Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists. Oncogene 33, 671-676 (2014).
30. T. K. Oberoi, T. Dogan, J. C. Hocking, R. P. Scholz, J. Mooz, C. L. Anderson, C. Karreman, D. Meyer zu Heringdorf, G. Schmidt, M. Ruonala, K. Namikawa, G. S. Harms, A. Carpy, B. Macek, R. W. Köster, K. Rajalingam, IAPs regulate the plasticity of cell migration by directly targeting Rac1 for degradation. EMBO J. 31, 14-28 (2012).
31. T. Dogan, G. S. Harms, M. Hekman, C. Karreman, T. K. Oberoi, E. S. Alnemri, U. R. Rapp, K. Rajalingam, X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nat. Cell Biol. 10, 1447-1455 (2008).
32. J. Liu, D. Zhang, W. Luo, Y. Yu, J. Yu, J. Li, X. Zhang, B. Zhang, J. Chen, X. R. Wu, G. Rosas-Acosta, C. Huang, X-linked inhibitor of apoptosis protein (XIAP) mediates cancer cell motility via Rho GDP dissociation inhibitor (RhoGDI)-dependent regulation of the cytoskeleton. J. Biol. Chem. 286, 15630-15640 (2011).
33. J. Yu, D. Zhang, J. Liu, J. Li, Y. Yu, X. R. Wu, C. Huang, RhoGDI SUMOylation at Lys-138 increases its binding activity to Rho GTPase and its inhibiting cancer cell motility. J. Biol. Chem. 287, 13752-13760 (2012).
34. E. R. Geisbrecht, D. J. Montell, A role for Drosophila IAP1-mediated caspase inhibition in Rac-dependent cell migration. Cell 118, 111-125 (2004).
35. T. Dohi, K. Okada, F. Xia, C. E. Wilford, T. Samuel, K. Welsh, H. Marusawa, H. Zou, R. Armstrong, S. Matsuzawa, G. S. Salvesen, J. C. Reed, D. C. Altieri, An IAP-IAP complex inhibits apoptosis. J. Biol. Chem. 279, 34087-34090 (2004).
36. P. Fortugno, E. Beltrami, J. Plescia, J. Fontana, D. Pradhan, P. C. Marchisio, W. C. Sessa, D. C. Altieri, Regulation of survivin function by Hsp90. Proc. Natl. Acad. Sci. U.S.A. 100, 13791-13796 (2003).
37. B. H. Kang, F. Xia, R. Pop, T. Dohi, M. Socolovsky, D. C. Altieri, Developmental control of apoptosis by the immunophilin aryl hydrocarbon receptor-interacting protein (AIP) involves mitochondrial import of the survivin protein. J. Biol. Chem. 286, 16758-16767 (2011).
38. J. C. Ghosh, T. Dohi, B. H. Kang, D. C. Altieri, Hsp60 regulation of tumor cell apoptosis. J. Biol. Chem. 283, 5188-5194 (2008).
39. A. S. Tan, J. W. Baty, M. V. Berridge, The role of mitochondrial electron transport in tumorigenesis and metastasis. Biochim. Biophys. Acta 1840, 1454-1463 (2014).
40. V. S. LeBleu, J. T. O'Connell, K. N. Gonzalez Herrera, H. Wikman, K. Pantel, M. C. Haigis, F. M. de Carvalho, A. Damascena, L. T. Domingos Chinen, R. M. Rocha, J. M. Asara, R. Kalluri, PGC-1a mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat. Cell Biol. 16, 992-1003 (2014).
41. T. Shiraishi, J. E. Verdone, J. Huang, U. D. Kahlert, J. R. Hernandez, G. Torga, J. C. Zarif, T. Epstein, R. Gatenby, A. McCartney, J. H. Elisseeff, S. M. Mooney, S. S. An, K. J. Pienta, Glycolysis is the primary bioenergetic pathway for cellmotility and cytoskeletal remodeling in human prostate and breast cancer cells. Oncotarget 6, 130-143 (2014).
42. P. E. Porporato, V. L. Payen, J. Perez-Escuredo, C. J. De Saedeleer, P. Danhier, T. Copetti, S. Dhup, M. Tardy, T. Vazeille, C. Bouzin, O. Feron, C. Michiels, B. Gallez, P. Sonveaux, A mitochondrial switch promotes tumor metastasis. Cell Rep. 8, 754-766 (2014).
43. R. A. Gatenby, R. J. Gillies, Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891-899 (2004).
44. G. L. Semenza, HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Invest. 123, 3664-3671 (2013).
45. C. Wu, S. B. Asokan, M. E. Berginski, E. M. Haynes, N. E. Sharpless, J. D. Griffith, S. M. Gomez, J. E. Bear, Arp2/3 is critical for lamellipodia and response to extracellular matrix cues but is dispensable for chemotaxis. Cell 148, 973-987 (2012).
46. I. R. Boldogh, L. A. Pon, Mitochondria on the move. Trends Cell Biol. 17, 502-510 (2007).
47. W. M. Saxton, P. J. Hollenbeck, The axonal transport of mitochondria. J. Cell Sci. 125, 2095-2104 (2012).
48. J. Zhao, J. Zhang, M. Yu, Y. Xie, Y. Huang, D. W. Wolff, P. W. Abel, Y. Tu, Mitochondrial dynamics regulates migration and invasion of breast cancer cells. Oncogene 32, 4814-4824 (2013).
49. S. P. Desai, S. N. Bhatia, M. Toner, D. Irimia, Mitochondrial localization and the persistent migration of epithelial cancer cells. Biophys. J. 104, 2077-2088 (2013).
50. D. N. Church, D. C. Talbot, Survivin in solid tumors:Rationale for development of inhibitors. Curr. Oncol. Rep. 14, 120-128 (2012).
51. A. Rauch, D. Hennig, C. Schafer, M. Wirth, C. Marx, T. Heinzel, G. Schneider, O. H. Kramer, Survivin and YM155: How faithful is the liaison? Biochim. Biophys. Acta 1845, 202-220 (2014).
52. S. Fulda, L. Galluzzi, G. Kroemer, Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 9, 447-464 (2010).
53. B. H. Kang, J. Plescia, H. Y. Song, M. Meli, G. Colombo, K. Beebe, B. Scroggins, L. Neckers, D. C. Altieri, Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 119, 454-464 (2009).
54. M. C. Caino, Y. C. Chae, V. Vaira, S. Ferrero, M. Nosotti, N. M. Martin, A. Weeraratna, M. O'Connell, D. Jernigan, A. Fatatis, L. R. Languino, S. Bosari, D. C. Altieri, Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells. J. Clin. Invest. 123, 2907-2920 (2013).
55. F. Li, E. J. Ackermann, C. F. Bennett, A. L. Rothermel, J. Plescia, S. Tognin, A. Villa, P. C. Marchisio, D. C. Altieri, Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell Biol. 1, 461-466 (1999).